|
1
|
Landgren O, Gilbert ES, Rizzo JD, Socié G,
Banks PM, Sobocinski KA, Horowitz MM, Jaffe ES, Kingma DW, Travis
LB, et al: Risk factors for lymphoprolipherative disorders after
allogeneic hematolopoietic cell transplantation. Blood.
113:4992–5001. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Seçkin D, Barete S, Euvrard S, Francès C,
Kanitakis J, Geusau A, Del Marmol V, Harwood CA, Proby CM, Ali I,
et al: Primary cutaneous posttransplant lymphoproliferative
disorders in solid organ transplant recipients: A multicenter
European case series. Am J Transplant. 13:2146–2153. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tanner JE and Alfieri C: The Epstein-Barr
virus and post-transplant lymphoproliferative diseases: Interplay
of immunosuppression, EBV, and the immune system in disease
pathogenesis. Transpl Infect Dis. 3:60–69. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Swerdlow SH, Webber SA, Chadburn A and
Ferry JA: Post-transplant lymphoproliferative disordersWHO
Classification of Tumours of Haematopoietic and Lymphoid Tissues.
Swerdlow SH, Campo E, Harris NL, Jafffe ES, Pileri SA, Stein H,
Thiele J and Vardiman JW: 4th. International Agency for Research on
Cancer; Lyon: pp. 343–349. 2008
|
|
5
|
Trofe J, Beebe TM, Buell JF, Hanaway MJ,
First MR, Alloway RR, Gross TG and Woodle ES: Posttransplant
malignancy. Prog Transplant. 14:193–200. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nassi L and Gaidano G: II. Challenges in
the management of post-transplant lymphoproliferative disorder.
Hematol Oncol. 33(Suppl 1): S96–S99. 2015. View Article : Google Scholar
|
|
7
|
Dierickx D, Tousseyn T and Gheysens O: How
I treat posttransplant lymphoproliferative disorders. Blood.
126:2274–2283. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dierickx D, Tousseyn T, Sagaert X, Fieuws
S, Wlodarska I, Morscio J, Brepoels L, Kuypers D, Vanhaecke J,
Nevens F, et al: Single-center analysis of biopsy-confirmed
posttransplant lymphoproliferative disorder: Incidence,
clinicopathological characteristics and prognostic factors. Leuk
Lymphoma. 54:2433–2440. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Choquet S, Trappe R, Leblond V, Jäger U,
Davi F and Oertel S: CHOP-21 for the treatment of post-transplant
lymphoproliferative disorders (PTLD) following solid organ
transplantation. Haematologica. 92:273–274. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Choquet S, Leblond V, Herbrecht R, Socié
G, Stoppa AM, Vandenberghe P, Fischer A, Morschhauser F, Salles G,
Feremans W, et al: Efficacy and safety of rituximab in B-cell
post-transplantation lymphoproliferative disorders: Results of a
prospective multicenter phase 2 study. Blood. 107:3053–3057. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Oertel SH, Verschuuren E, Reinke P,
Zeidler K, Papp-Váry M, Babel N, Trappe RU, Jonas S, Hummel M,
Anagnostopoulos I, et al: Effect of anti-CD 20 antibody rituximab
in patients with post-transplant lymphoproliferative disorder
(PTLD). Am J Transplant. 5:2901–2906. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Trappe R, Oertel S, Leblond V, Mollee P,
Sender M, Reinke P, Neuhaus R, Lehmkuhl H, Horst HA, Salles G, et
al: Sequential treatment with rituximab followed by CHOP
chemotherapy in adult B-cell post-transplant lymphoproliferative
disorder (PTLD): The prospective international multicentre phase 2
PTLD-1 trial. Lancet Oncol. 13:196–206. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Au WY, Pang A, Choy C, Chim CS and Kwong
YL: Quantification of circulating Epstein-Barr virus (EBV) DNA in
the diagnosis and monitoring of natural killer cell and
EBV-positive lymphomas in immunocompetent patients. Blood.
104:243–249. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gulley ML and Tang W: Using Epstein-Barr
viral load assays to diagnose, monitor, and prevent posttransplant
lymphoproliferative disorder. Clin Microbiol Rev. 23:350–366. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Law MF, Poon WL, Ng KS, Chan HN, Lai HK,
Ha CY, Ng C, Yeung YM and Yip SF: Quantification of plasma
Epstein-Barr virus DNA for assessing treatment response in a
patient with plasmablastic lymphoma. Ann Hematol. 91:789–791. 2012.
View Article : Google Scholar : PubMed/NCBI
|
